Acute myeloid leukemia
Conditions
Interventions
single arm:Desitabine combined with chidamide
Sponsors
The First Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1) aged 55 years, male or female; 2) acute myeloid leukemia was first diagnosed according to the classification of myeloid tumors and acute leukemia revised by the world health organization (WHO) in 2016; 3) ECOG behavior status score is 0-3; 4) expected survival time >= 3 months; 5) no serious heart, lung, liver or kidney diseases; 6) did not receive radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell transplantation within 4 weeks before enrollment; 7) ability to understand and be willing to sign the informed consent for this test.
Exclusion criteria
Exclusion criteria: 1) previous allergy to drugs included in the test protocol or to drugs with similar chemical structure to the tested drugs; 2) pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures; 3) active infection; 4) patients who take drugs or drink excessively for a long time and thus affect the evaluation of test results; 5) patients suffering from mental disorders or other conditions cannot obtain informed consent and cannot cooperate with the requirements of completing the experimental treatment and examination procedures; 6) have clinical significance in patients with a history of QTc duration between (men > 450 ms, women >470 ms), ventricular tachycardia (VT), atrial fibrillation (AF), the above II degrees heart block, the onset of myocardial infarction (MI) within 1 year, congestive heart failure (CHF), and symptomatic drug treatment of patients with coronary heart disease; 7) patients whose b-mode ultrasound showed the width of fluid dark area in the pericardial cavity at the end of diastole >= 10mm; 8) patients receiving organ transplantation; 9) patients with new thrombosis, embolism, cerebral hemorrhage or other diseases or medical history within the last month; 10) less than 6 weeks after major organ surgery; 11) the investigator determines that the participant is not suitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Countries
China
Contacts
Public ContactYinghua Li
The First Affiliated Hospital of Harbin Medical University
Outcome results
None listed